Real-World Effectiveness of Sitagliptin as Add-On Therapy in Patients With Type 2 Diabetes Mellitus

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Postgraduate medicine

• Publication date

  2014-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3810/pgm.2014.05.2768PMID 24918804
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Trends of ABC control 2006-2011: a National Survey of Diabetes Health Promotion Institutes in Taiwan.

  2013cited by this paper
• Standards of Medical Care in Diabetes—2013

  2012cited by this paper
• Effect of initial combination therapy with sitagliptin and metformin on β‐cell function in patients with type 2 diabetes

  2012cited by this paper
• The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Neuroprotective properties of GLP-1: theoretical and practical applications

  2011cited by this paper
• The effect of initial therapy with the fixed‐dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus

  2011cited by this paper
• Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis

  2011cited by this paper
• Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone

  2011cited by this paper
• Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

  2011cited by this paper
• Effect of Sitagliptin as Add-on Therapy in Elderly Type 2 Diabetes Patients With Inadequate Glycemic Control in Taiwan †

  2011cited by this paper
• Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double‐blind trial

  2010cited by this paper
• Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

  2010cited by this paper
• Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study

  2010cited by this paper
• Use of silkworms for identification of drug candidates having appropriate pharmacokinetics from plant sources

  2010cited by this paper
• Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

  2010cited by this paper
• Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.

  2009cited by this paper
• Incretin therapies: effects beyond glycemic control.

  2009cited by this paper
• Incretin therapies: effects beyond glycemic control.

  2009cited by this paper
• Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

  2008cited by this paper
• Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes

  2008cited by this paper
• Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.

  2008cited by this paper
• Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.

  2008cited by this paper
• Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortality

  2007cited by this paper
• Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  2007cited by this paper
• Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.

  2007cited by this paper
• Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

  2006cited by this paper
• Epidemic obesity and type 2 diabetes in Asia.

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

  2002cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Prescribing patterns in primary health care in Taiwan.

  1995cited by this paper
• Prescribing patterns in primary health care in Taiwan.

  1995cited by this paper

• Revisiting the Cardiorenal Safety of Sitagliptin in Type 2 Diabetes Mellitus: A Literature Review.

  2025cites this paper
• Understanding the Preference of a Dipeptidyl Peptidase-4 Inhibitor and its Combination Therapy in Type 2 Diabetes Mellitus among Indian Clinicians

  2024cites this paper
• Efficacy of Insulin Titration Driven by SMS in Improving Glycemic Control in People with Type 2 Diabetes

  2023cites this paper
• Glucose‐lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase‐4 inhibition

  2021cites this paper
• Efficacy and Safety of Sitagliptin in Type 2 Diabetic Libyan patients

  2021cites this paper
• Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios

  2018cites this paper
• Comparative effectiveness of sitagliptin and vildagliptin in the management of patients with type 2 diabetes mellitus undergoing haemodialysis: an Indian rural tertiary care centre experience

  2018cites this paper
• Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients

  2017cites this paper
• Sitagliptin: A Review in Type 2 Diabetes

  2017cites this paper
• Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy

  2016cites this paper
• Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives

  2016cites this paper
• Sitagliptin: Is It Effective in Routine Clinical Practice?

  2015cites this paper
• Sitagliptin for Type 2 diabetes: a 2015 update

  2015cites this paper